TDZD-8 has been used to study the role of GSK-3 in maintaining MLL leukemia stem cell transcriptional program. TDZD-8 has also been used to analyze its effect on neural functions of the mouse olfactory bulb.
Glycogen Synthase Kinase-3 is a highly conserved ubiquitously expressed serine/threonine protein kinase involved in signal transduction cascades of multiple cellular processes. TDZD-8 is a thiadiazolidinone (TDZD) analogue that acts as a highly selectiv
ChEBI: TDZD-8 is a member of the class of thiadiazolidines that is 1,2,4-thiadiazolidine-3,5-dione which is substituted by a methyl group at position 2 and by a benzyl group at position 4. It is a non-ATP competitive inhibitor of glycogen synthase kinase 3beta (GSK3beta). An experimental compound which was being developed for the potential treatment of Alzheimer's disease. It has a role as an EC 2.7.11.26 (tau-protein kinase) inhibitor, an apoptosis inducer, an antineoplastic agent, a neuroprotective agent and an anti-inflammatory agent. It is a thiadiazolidine and a member of benzenes.
A cell-permeable, thiadiazolidinone (TDZD) analog that acts as a highly selective, non-ATP-competitive inhibitor of GSK-3β (IC50 = 2 μM). Inhibits Flt-3 and PKC activities (IC50 = 673 nM and 1.4-5.5 μM, respectively). Does not significantly affect the activities of Cdk1/cyclin B, CK-II, PKA, or PKC (IC50 >100 μM). Shown to inhibit collagen- and thrombin-induced platelet aggregation.
tdzd-8 is an inhibitor of glycogen synthase kinase-3β (gsk-3β) with ic50 value of 1.4μm [1].tdzd-8 is a potent inhibitor of gsk-3β. it is found to act as a noncompetitive inhibitor of atp binding. tdzd-8 is selective against gsk-3β over other protein kinases including pka, casein kinase ii and cyclin dependent kinase 1 (cdk-1/cyclin b). however, it is also reported that tdzd-8 can inhibit the protein kinase c isoforms pkcβi and pkcδ with ic50 values of 1.4μm and 1.1μm, respectively [1, 2].in cellular assay, tdzd-8 is found to decrease pdt-induced necrosis of neurons and decrease pdt-induced apoptosis of glial cells through inhibiting gsk-3β as well as pkc. besides that, tdzd-8 also has anti-leukemia activity in many primary human leukemia cells. it is probably due to its inhibition of pkc and flt3 [3].
[1] komandirov m a, knyazeva e a, fedorenko y p, et al. on the role of phosphatidylinositol 3-kinase, protein kinase b/akt, and glycogen synthase kinase-3β in photodynamic injury of crayfish neurons and glial cells. journal of molecular neuroscience, 2011, 45(2): 229-235.
[2] martinez a, alonso m, castro a, et al. first non-atp competitive glycogen synthase kinase 3 β (gsk-3β) inhibitors: thiadiazolidinones (tdzd) as potential drugs for the treatment of alzheimer's disease. journal of medicinal chemistry, 2002, 45(6): 1292-1299.
[3] guzman m l, li x, corbett c a, et al. rapid and selective death of leukemia stem and progenitor cells induced by the compound 4-benzyl, 2-methyl, 1, 2, 4-thiadiazolidine, 3, 5 dione (tdzd-8). blood, 2007, 110(13): 4436-4444.
